Clinical Trial Update: Oral PTH(1-34) PK and PD Study in Patients With Hypoparathyroidism [Phase 2]

View source ↗

Summary

Phase 2 study update evaluating the pharmacokinetics and pharmacodynamics of oral PTH(1-34) in patients with hypoparathyroidism.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypoparathyroidism

Drugs mentioned

• PTH(1-34) oral (parathyroid hormone fragment (PTH 1-34) oral)

Snippet

Sponsor: Entera Bio Ltd. | Conditions: Hypoparathyroidism | Phase 2 | Status: COMPLETED